Lovely meeting of the #German #sarcoma group followed by a nice dinner to celebrate Peter Hohenberger with a very warm & emotional #farewell that he really deserves for all he did to #sarcoma patient’s throughout his career. CTOS EORTC SPAGN Society of Surgical Oncology

Giants of European oncology making the case for the importance of academic, non-for-profit, multidisciplinary clinical research at EORTC’s 60th Anniversary in Brussels today

Working on ‘rarity’ not just as an obvious ethical imperative: also compatible with substantial impacts, possibly the size of a couple of big killers in oncology, looking at the denominator of success for all #RareCancers: health care networking & appropriate patient referral!

Our EU Joint Action paving the way to 7 new European Networks of Expertise launched today in Milan, coordinated by Istituto Nazionale Tumori: building a new kind of health care networking in the EU, hoping to innovatively serve cancer centers & networks for all cancer patients

Corso Residenziale 🔸Decidere in oncologia. Uso dell’analisi decisionale in: melanoma, sarcomi e GIST, tumori della testa e collo Soft skill per la decisione clinica collaborativa Milano | 23-24.01.23 ow.ly/wT7r50MhZpv Responsabile Scientifico: Paolo G. Casali Paolo G Casali

Today is #WorldCancerDay. 1 in 5 cancers is a rare cancer. There are an estimated 5.1 million people living with rare cancer across Europe, with about 650,000 new diagnoses annually, and they represent about 22% of all cancer cases diagnosed in Europe.

Today is #RareDiseaseDay! It is the globally-coordinated movement on rare diseases, including rare cancers, which aims for equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Click here : rarediseaseday.org

My point: development of drugs in oncology can be agnostic, but then their clinical positioning should be investigated within the specific cancer (however defined)…

Thanks #ESMOSarcomaandrarecancers23 for allocating a session to EU networking. The Joint Actions CRANE and JANE are there to collect the needs and requests of the European oncology community to optimize future Network of Comprehensive Cancer Centers and Networks of Expertise!

We cannot overstate the importance of accurate diagnosis & effective treatment in the fight against cancer. This is why the Joint Action on Networks of Expertise (#JANE) was created, presented today by Paolo G Casali More: europa.eu/!KQVvcV #EUCancerPlan #EU4Health #EWAC2023

My take: our common advocacy about healthcare networking in the EU should focus on viewing it as networking of national/regional networking and allowing the role of full partners to scientific/professional societies as well as patient advocacy groups.

Thanks the new Spanish EU Presidency for hosting the EU Joint Action on Networks of Expertise. Cancer care networking can be such an added value of Europe that its many challenges must be addressed assertively, first working on the interplay between the EU and the national level!

Join the first EURACAN virtual grand round, with Dr Patricia Pautier from Gustave Roussy 🗓️Friday 5 April 1:00 CET > To register, send an email to [email protected]

📢Registrations open for the third EURACAN grand round to learn more about the results of the IMADGIST study presented by Prof Le Cesne from Gustave Roussy. 🗓️ 7 June ; 13:00 CET on Zoom Send an email to [email protected] to receive the link

📢Registrations still open for the next G1 virtual grand round. Send an email to [email protected] to receive the link.

🎗️July is Sarcoma Awareness Month!! The mission of #ISG is to improve the quality of care for patients battling #sarcoma. Visit #ISG website to learn more about our goals and join us in spreading awareness and hope 💪💖 #SarcomaAwarenessMonth italiansarcomagroup.org

All saddened by losing his strong interpretation of a medical specialty in transformation, his total commitment to a disease, his humor in multidisciplinarity…

Implementing precision medicine implies a paradigm change in research methodology; implementing personalized medicine implies a paradigm change in methodology of clinical decision-making. Explainable AI is part of the solutions, but these should be made explicit.

EU Joint Action on Networks of Expertise (JANE 1) just closed, knocking on the EU Parliament’s doors asking to politically address the many challenges of cancer healthcare networking. JANE 2 ready to start and give birth to seven new Networks of Expertise on cancer in the EU…

Today marks the launch of one of the biggest ever Joint Actions on cancer - backed by €40.5 million under #EU4Health. This will bring together the highest expertise and improve cooperation, to support our fight against cancer across the EU. #HealthUnion ec.europa.eu/newsroom/sante…